Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Frailty × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 360 Brain Neoplasms 138 Glioma 137 Gliosarcoma 120 Astrocytoma 103 Central Nervous System Neoplasms 97 Oligodendroglioma 66 Melanoma 59 Neuroblastoma 39 Medulloblastoma 28 Neoplasms 26 Recurrence 24 Ependymoma 24 Neoplasm Metastasis 23 Sarcoma, Ewing 19 Sarcoma 17 Rhabdomyosarcoma 16 Diffuse Intrinsic Pontine Glioma 15 Ovarian Neoplasms 13 Breast Neoplasms 13 Lymphoma 12 Neuroendocrine Tumors 11 Small Cell Lung Carcinoma 10 Lung Neoplasms 10 Choroid Plexus Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Osteosarcoma 9 Neuroectodermal Tumors, Primitive 9 Optic Nerve Glioma 8 Neuroectodermal Tumors, Primitive, Peripheral 8

Interventions

Geriatric Assessment 9 Standard of Care 3 Preoperative Exercise 3 Observation 2 Nutritional Support 2 Exercise 2 peflavit 1 microcrystalline cellulose 1 fisetin 1 epigallocatechin gallate 1 diacetamate 1 cabozantinib 1 Ultrasonography 1 Tretinoin 1 Therapeutics 1 Temozolomide 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Spectroscopy, Near-Infrared 1 Restraint, Physical 1 Quercetin 1 Qigong 1 Psychosocial Intervention 1 Protons 1 Photons 1 Nutrition Assessment 1 Methods 1 Immunonutrition Diet 1 Flavonoids 1 Enhanced Recovery After Surgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡